Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice

Melanoma Research

Volumn 23, Issue 2, 2013, Pages 114-124

  Roh, Mi Ryung ^a   Zheng, Zhenlong ^a,d   Kim, Hyun Sook ^a   Jeung, Hei Cheul ^b   Rha, Sun Young ^b   Chung, Kee Yang ^c  

^a Cutaneous Biology Research Institute   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d YANBIAN UNIVERSITY   (China)

Author keywords

interferon; lymph node metastasis; lymphangiogenesis; melanoma

Indexed keywords

BETA1A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

EID: 84874950693     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835e7713     Document Type: Article

References (61)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 2011; 12:144-152.
3. Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, et al. High-and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000; 18:2444-2458.
4. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003; 29:241-252.
5. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010; 102:493-501.
6. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14:7-17.
7. Tobler NE, Detmar M. Tumor and lymph node lymphangiogenesis-impact on cancer metastasis. J Leukoc Biol 2006; 80:691-696.
8. Tammela T, Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010; 140:460-476.
9. Kerjaschki D, Bago-Horvath Z, Rudas M, Sexl V, Schneckenleithner C, Wolbank S, et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J Clin Invest 2011; 121:2000-2012.
10. Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C, et al. Inhibition of angiogenesis and vascular tumor growth by interferonproducing cells: a gene therapy approach. Am J Pathol 2000; 156: 1381-1393.
11. Dong Z, Greene G, Pettaway C, Dinney CP, Eue I, Lu W, et al. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. Cancer Res 1999; 59:872-879.
12. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-6281.
13. Von Marschall Z, Scholz A, Cramer T, Schafer G, Schirner M, Oberg K, et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003; 95: 437-448.
14. Rebhun RB, Lazar AJ, Fidler IJ, Gershenwald JE. Impact of sentinel lymphadenectomy on survival in a murine model of melanoma. Clin Exp Metastasis 2008; 25:191-199.
15. Kunstfeld R, Wickenhauser G, Michaelis U, Teifel M, Umek W, Naujoks K, et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a 'humanized' SCID mouse model. J Invest Dermatol 2003; 120:476-482.
16. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004; 45:47-54.
17. Cornejo P, Vanaclocha F, Polimon I, Del Rio R. Intralesional interferon treatment of lentigo maligna. Arch Dermatol 2000; 136:428-430.
18. Rapprich H, Hagedorn M. Intralesional therapy of metastatic spreading melanoma with beta-interferon. J Dtsch Dermatol Ges 2006; 4:743-746.
19. Kawada K, Kawano T, Nagai K, Nishikage T, Nakajima Y, Tokairin Y, et al. Local injection of interferon beta in malignant melanoma of the esophagus as adjuvant of systemic pre-and postoperative DAV chemotherapy: case report with 7 years of long-term survival. Gastrointest Endosc 2007; 66:408-410.
20. Kubo H, Ashida A, Matsumoto K, Kageshita T, Yamamoto A, Saida T. Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res 2008; 300:297-301.
21. Matsumoto K, Kubo H, Murata H, Uhara H, Takata M, Shibata S, et al. A pilot study of human interferon beta gene therapy for patients with advanced melanoma by in vivo transduction using cationic liposomes. Jpn J Clin Oncol 2008; 38:849-856.
22. Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, et al. In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol 1995; 22:631-636.
23. Borden EC, Jacobs B, Hollovary E, Rybicki L, Elson P, Olencki T, et al. Gene regulatory and clinical effects of interferon beta in patients with metastatic melanoma: a phase II trial. J Interferon Cytokine Res 2011; 31:433-440.
24. Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, et al. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 1990; 95:231S-237S.
25. Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997; 17:355-367.
26. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7:1821-1831.
27. Hong YK, Chung DS, Joe YA, Yang YJ, Kim KM, Park YS, et al. Efficient inhibition of in vivo human malignant glioma growth and angiogenesis by interferon-beta treatment at early stage of tumor development. Clin Cancer Res 2000; 6:3354-3360.
28. Zhang H, Koty PP, Mayotte J, Levitt ML. Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp Cell Res 1999; 247:133-141.
29. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67:227-264.
30. Borden EC. Review: Milstein Award Lecture: interferons and cancer: where from here? J Interferon Cytokine Res 2005; 25:511-527.
31. Schiller JH, Willson JK, Bittner G, Wolberg WH, Hawkins MJ, Borden EC. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J Interferon Res 1986; 6:615-625.
32. Krasagakis K, Garbe C, Kruger S, Orfanos CE. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or-gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 1991; 97:364-372.
33. Gomi K, Morimoto M, Nakamizo N. Antitumor effect of human recombinant interferon-beta against human melanomas transplanted into nude mice. J Pharmacobiodyn 1984; 7:951-961.
34. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992; 84:1185-1190.
35. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
36. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
37. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
38. Mihm MC Jr, Clark WH Jr, Reed RJ. The clinical diagnosis of malignant melanoma. Semin Oncol 1975; 2:105-118.
39. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.
40. Ferrara N, HenzelWJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161:851-858.
41. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994; 144:329-336.
42. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999; 189:546-551.
43. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992; 326:1456-1463.
44. Kaban LB, Mulliken JB, Ezekowitz RA, Ebb D, Smith PS, Folkman J. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999; 103:1145-1149.
45. Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res 2008; 28:553-561.
46. Meier F,Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147:62-70.
47. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20:672-682.
48. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7:192-198.
49. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7:186-191.
50. Dadras SS, Paul T, Bertoncini J, Brown LF, Muzikansky A, Jackson DG, et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003; 162:1951-1960.
51. Dadras SS, Lange-Asschenfeldt B,Velasco P, Nguyen L,Vora A, Muzikansky A, et al. Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005; 18:1232-1242.
52. Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, Gonzalez-Cao M, et al. Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 2006; 59:166-173.
53. Skobe M, Hamberg LM, Hawighorst T, Schirner M,Wolf GL, Alitalo K, et al. Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol 2001; 159:893-903.
54. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002; 2:573-583.
55. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005; 201:1089-1099.
56. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M. VEGFC-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007; 109:1010-1017.
57. Harrell MI, Iritani BM, Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 2007; 170:774-786.
58. Wobser M, Siedel C, Schrama D, Brocker EB, Becker JC, Vetter-Kauczok CS. Expression pattern of the lymphatic and vascular markers VEGFR-3 and CD31 does not predict regional lymph node metastasis in cutaneous melanoma. Arch Dermatol Res 2006; 297:352-357.
59. Clarijs R, Schalkwijk L, Hofmann UB, Ruiter DJ, de Waal RM. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res 2002; 62:7059-7065.
60. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009; 45:1407-1414.
61. Kataru RP, Kim H, Jang C, Choi DK, Koh BI, Kim M, et al. T lymphocytes negatively regulate lymph node lymphatic vessel formation. Immunity 2011; 34:96-107.